Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $12.19B | $112.79 | $122.60 | 8.70% | Buy | 5 | 39.18% | 137.99% | 172.24% | 136.79% | |||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $3.00B | $23.89 | $38.67 | 61.89% | Strong Buy | 3 | 22.15% | 116.23% | 162.86% | 73.53% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $33.28B | $248.68 | $356.19 | 43.23% | Strong Buy | 16 | 20.98% | 28.36% | 186.00% | 45.31% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $5.95B | $76.27 | $91.29 | 19.69% | Strong Buy | 7 | 19.35% | 39.16% | 38.00% | 27.74% | |||
| HALO | HALOZYME THERAPEUTICS INC | $12.17B | $107.20 | $101.83 | -5.01% | Buy | 6 | 11.52% | 48.93% | 769.40% | 42.85% | |||
| RPRX | ROYALTY PHARMA PLC | $33.70B | $58.61 | $63.50 | 8.34% | Strong Buy | 6 | 15.38% | 49.21% | 42.19% | 20.83% | |||
| KRYS | KRYSTAL BIOTECH INC | $10.27B | $347.00 | $374.33 | 7.88% | Strong Buy | 7 | 29.78% | 18.85% | 63.71% | 57.71% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $12.71B | $65.68 | $92.00 | 40.07% | Strong Buy | 14 | 13.33% | 152.25% | 25.90% | 13.97% | |||
| VCEL | VERICEL CORP | $1.96B | $38.34 | $62.67 | 63.45% | Strong Buy | 3 | 14.77% | 40.75% | 22.72% | 16.72% | |||
| ADMA | ADMA BIOLOGICS INC | $2.07B | $9.23 | $17.50 | 89.60% | Buy | 3 | 13.23% | 17.15% | 83.21% | 49.64% | |||
| TECH | BIO-TECHNE CORP | $11.31B | $72.12 | $68.33 | -5.25% | Hold | 11 | 8.35% | 31.76% | 20.05% | 16.34% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $713.20M | $12.01 | $26.88 | 123.77% | Strong Buy | 8 | 18.48% | 11.46% | 77.72% | 55.88% | |||
| TGTX | TG THERAPEUTICS INC | $8.25B | $53.89 | $64.00 | 18.76% | Buy | 4 | 28.02% | 8.98% | 101.32% | 37.33% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $15.96B | $245.80 | $286.24 | 16.45% | Strong Buy | 17 | 6.18% | 23.84% | 43.06% | 18.66% | |||
| EXEL | EXELIXIS INC | $13.91B | $56.12 | $52.00 | -7.34% | Hold | 11 | 10.77% | 15.17% | 66.89% | 49.45% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $130.64B | $515.44 | $553.83 | 7.45% | Strong Buy | 12 | 9.81% | 14.07% | 36.48% | 26.94% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $5.67B | $284.47 | $352.29 | 23.84% | Strong Buy | 7 | 16.19% | 13.23% | 29.02% | 12.85% | |||
| MDXG | MIMEDX GROUP INC | $666.13M | $4.57 | $7.33 | 60.46% | Strong Buy | 3 | 5.14% | 105.05% | 13.77% | 10.58% | |||
| SPRO | SPERO THERAPEUTICS INC | $65.81M | $1.13 | N/A | N/A | N/A | N/A | -14.78% | 128.15% | N/A | N/A | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.42B | $41.52 | $47.67 | 14.80% | Buy | 6 | 11.54% | 16.79% | 23.24% | 16.92% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $80.46B | $781.49 | $802.84 | 2.73% | Strong Buy | 19 | 9.46% | 18.78% | 24.05% | 18.28% | |||
| UTHR | UNITED THERAPEUTICS CORP | $21.32B | $497.11 | $647.38 | 30.23% | Strong Buy | 8 | 8.71% | 5.78% | 30.47% | 27.01% | |||
| INCY | INCYTE CORP | $24.62B | $121.47 | $121.25 | -0.18% | Buy | 16 | 4.56% | 8.90% | 12.85% | 10.36% | |||
| VCYT | VERACYTE INC | $3.29B | $40.87 | $55.44 | 35.66% | Strong Buy | 9 | 9.69% | 0.25% | 11.84% | 11.06% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.